Literature DB >> 28449227

Apremilast for a psoriasis patient with HIV and hepatitis C.

S P Reddy1, V V Shah2, J J Wu3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28449227     DOI: 10.1111/jdv.14301

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

2.  Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities.

Authors:  Caleb Jeon; Mio Nakamura; Sahil Sekhon; Di Yan; Jashin J Wu; Wilson Liao; Tina Bhutani
Journal:  JAAD Case Rep       Date:  2017-10-06

3.  COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.

Authors:  C Mugheddu; L Pizzatti; S Sanna; L Atzori; F Rongioletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-04       Impact factor: 6.166

Review 4.  Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.

Authors:  Alfonso Motolese; Manuela Ceccarelli; Laura Macca; Federica Li Pomi; Ylenia Ingrasciotta; Giuseppe Nunnari; Claudio Guarneri
Journal:  Biomedicines       Date:  2022-01-21

5.  Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-13       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.